Promedius develops Osteo Signal, an AI-based screening solution that analyzes routine chest radiographs to assess osteoporosis risk in about three seconds and identify at-risk patient groups without additional tests. Osteo Signal was designated an innovative medical device in 2024 and received approval from the Korean Ministry of Food and Drug Safety in 2025; the company has also secured regulatory approvals in Vietnam and Indonesia and is seeking FDA and CE/MDR clearances by the end of the year. Promedius has built partnerships with global medical device companies such as Siemens Healthineers and secured strategic investors including Daewoong Pharmaceutical and Naver to support commercial rollout. The company aims to commercialize nationally and expand internationally while broadening its platform to address healthy aging conditions like sarcopenia, metabolic and cardiovascular diseases. Its total funding now exceeds 35 billion won following the recent Series B raise of 21.5 billion won.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Jun 2026